EVOKE PHARMA, INC. Deferred Tax Assets, in Process Research and Development

EVOKE PHARMA, INC. Deferred Tax Assets, in Process Research and Development

EVOKE PHARMA, INC. had Deferred Tax Assets, in Process Research and Development of $168.00 thousand as of 2024-12-31, per its 10-K filed 2025-03-13.

Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross

us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment · last filed 2025-03-13

• 2024-12-31: Deferred Tax Assets, in Process Research and Development $168.00K.
• 2023-12-31: Deferred Tax Assets, in Process Research and Development $161.00K.
• 2022-12-31: Deferred Tax Assets, in Process Research and Development $125.00K.